Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q4 2021 Earnings Presentation
9 slides from Angiodynamics's earnings presentation, Jul 13, 2021
Slide 1: Fourth Quarter 2021 Earnings Presentation
ANGIODYNAMICS Fourth Quarter 2021 Earnings Presentation July 13, 2021 1
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca
Slide 3: Corporate Developments – Q4 Highlights
Corporate Developments – Q4 Highlights • Continued focused investment in our 3 key technology platforms: Auryon, AngioVac & NanoKnife • YOY comparisons are significantly impacted by the COVID-19 global pandemic • Procedural volumes continued to rebound in Q4 • AngioVac cases continued their sequenti
Slide 4: Fourth Quarter and FY2021 Highlights
Fourth Quarter and FY2021 Highlights Financial Performance Product Family Sales Growth Over Prior Year Periods YOY Endovascular Therapies (formerly VIT) Q4 FY2021 FY2021 Q4 FY2021 Q4 FY2020 $ in thousands (except per share data) Change AngioVac® 108% 47% Auryon NA* NA* Revenue $76,842 $58,332 31.7%
Slide 5: Fourth Quarter and FY2021 Highlights – Additional Detail
Fourth Quarter and FY2021 Highlights Sales Growth Over Prior Year Periods – Additional Detail Med Tech Q4 FY2021 FY2021 Auryon NA** NA** Mechanical Thrombectomy* 62% 32% NanoKnife® Disposables 42% 13% NanoKnife® Capital (77%) (48%) Med Device Q4 FY2021 FY2021 Solero® Microwave 38% 11% BioSentry 93%
Slide 6: Fourth Quarter and FY2021 Results (unaudited)
Fourth Quarter and FY2021 Results (unaudited) $ in thousands (except per share data) Q4 FY2021 Q4 FY2020 Change FY2021 FY2020 Change Revenue $76,842 $58,332 31.7% $291,010 $264,157 10.2% Endovascular Therapies (formerly VIT) $38,071 $22,090 72.3% $135,079 $112,706 19.9% Vascular Access $24,462 $23,7
Slide 7: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 7
Slide 8: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Reconciliation of Net Loss to Adjusted Net Income and EPS EBITDA (in thousands, except per share data) (in thousands) (1) Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company’s acquisition of
Slide 9: AngioDynamics
i>) angiodynamics